News
Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly improved” as compared to placebo—the second positive readout for the asset this week.
FEATURED STORIES
While the pathogen appears unlikely to trigger a pandemic, analysts see potential for Moderna to build goodwill amid a period of political pressure on vaccine manufacturers.
Clinical trial setbacks have limited the near-term opportunities for some of Daiichi Sankyo’s ADCs but the drug developer is betting near-term readouts will catapult it into the top tier of oncology companies in the coming years.
BioSpace analyzed the pay ratio across 10 major pharmaceutical companies to determine which CEOs were paid the most relative to typical employees. J&J, Eli Lilly and Pfizer once again topped the list.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisions—the CDC and the FDA’s two primary review units.
THE LATEST
The new funds will go toward advancing Congruence’s Revenir™ platform, a computational tool that models diseases that come from cellular proteins misfolding in order to understand them better.
Jennifer Doudna will act as Chief Science Advisor to build a Scientific Advisory Board for Sixth Street, advising the investment firm on CRISPR-related opportunities.
After allegations of bullying became public, Dr. Eric Lander, the director of the federal government’s Office of Science and Technology Policy, resigned from his executive branch role.
Bayer isn’t the only company to announce changes to its leadership team this morning. Editas, Biogen, Takeda, Merck and Vedere Bio also announced leadership changes.
Weston Miller, M.D., senior medical director of clinical development at Astellas Gene Therapies, called the positive interim and tolerability data an important waypoint.
ALZ-801 is administered orally and works by blocking the formation of neurotoxic soluble amyloid oligomers that later lead to cognitive decline in Alzheimer’s patients.
Much of Amgen’s modest gains in the year can be attributed to its manufacturing partnership with Eli Lilly and an increase in sales for EVENITY.
The U.S. Food and Drug Administration announced they are investigating a possible death risk for TG Therapeutics’ Ukoniq (umbralisib).
The same advantage against HIV-1 possessed by a person with the inactive CCR5 variant potentially doubles as resistance to any virus that capitalizes on or manipulates that receptor.
To address that lack of diversity, Medable and CVS have forged a collaboration to improve patient access to clinical trial research.